Report
Louis-Clément AZAIS d'UHART
EUR 111.24 For Business Accounts Only

Analyse court terme - NOVARTIS : La moyenne mobile sert de support.

Le précédent sommet vient d'être franchi, ceci confirme la tendance haussière. Le prochain objectif est à 84,54 CHF. Le niveau d'invalidation est sous 72,70 CHF.

Arguments :
- La résistance majeure a été dépassée, mais elle est réintégrée. Les prix peuvent baisser.
- La moyenne...
Underlying
Novartis AG

Novartis is a multinational healthcare group based in Switzerland. Co. provides healthcare solutions that address the evolving needs of patients and societies worldwide. Co.'s broad portfolio includes innovative medicines, eye care products and cost-saving generic pharmaceuticals. Co.'s operations are organized along three operating divisions: Innovative Medicines Division; Sandoz Division; and Alcon Division. Co.'s operations are supported by the Novartis Institutes for BioMedical Research and Novartis Business Services.

Provider
Day By Day
Day By Day

​​DayByDay is an independent research company providing global macro and single stock analysis, recommendation and allocation based purely on behavioural finance methods. Those include long term cycle analysis, sentiment analysis, and technical trigger. DayByDay serves all clients in need of practical and precise publications to make effective market decisions, on any time horizon, from a few hours to a few years.

Analysts
Louis-Clément AZAIS d'UHART

Other Reports on these Companies
Other Reports from Day By Day

ResearchPool Subscriptions

Get the most out of your insights

Get in touch